Cornu M, Lemaitre T, Kieffer C, Voisin-Chiret AS. PROTAC 2.0: Expanding the frontiers of targeted protein degradation. Drug Discov Today. 2025;30:104376.

Article  CAS  PubMed  Google Scholar 

Li J, Chen X, Lu A, Liang C. Targeted protein degradation in cancers: orthodox PROTACs and beyond. Innovation. 2023;4:100413.

CAS  PubMed  PubMed Central  Google Scholar 

Casan JML, Seymour JF. Degraders upgraded: the rise of PROTACs in hematological malignancies. Blood. 2024;143:1218–30.

Article  CAS  PubMed  Google Scholar 

Yu Y, Hu W, Xu Y, Xu H-B, Gao J. Advancements in delivery Systems for Proteolysis-Targeting Chimeras (PROTACs): overcoming challenges and expanding biomedical applications. J Control Release. 2025;382:113719.

Article  CAS  PubMed  Google Scholar 

Yang C, Yang Y, Li Y, Ni Q, Li J. Radiotherapy-triggered proteolysis targeting chimera prodrug activation in tumors. J Am Chem Soc. 2023;145:385–91.

Article  CAS  PubMed  Google Scholar 

Alabi SB, Crews CM. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. J Biol Chem. 2021;296:100647.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98:8554–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu SS, Cui DR, Chen XY, Xiong XF, Zhao YC. PROTACs: an emerging targeting technique for protein degradation in drug discovery. Bioessays. 2018;40:1700247.

Article  Google Scholar 

Yang JL, Li YB, Aguilar A, Liu ZM, Yang CY, Wang SM. Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders. J Med Chem. 2019;62:9471–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Chen H, Liu Y, Shen Y, Meng F, Kaniskan HÜ, et al. Cancer selective target degradation by folate-caged PROTACs. J Am Chem Soc. 2021;143:7380–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Si R, Hai P, Zheng Y, Wang J, Zhang Q, Li Y, et al. Discovery of intracellular self-assembly protein degraders driven by tumor-specific activatable bioorthogonal reaction. Eur J Med Chem. 2023;257:115497.

Article  CAS  PubMed  Google Scholar 

Scheepstra M, Hekking KFW, van Hijfte L, Folmer RHA. Bivalent ligands for protein degradation in drug discovery. Comput Struct Biotec. 2019;17:160–76.

Article  CAS  Google Scholar 

Sakamoto KM. Protacs for treatment of cancer. Pediatr Res. 2010;67:505–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ottis P, Crews CM. Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy. ACS Chem Biol. 2017;12:892–8.

Article  CAS  PubMed  Google Scholar 

Nguyen C, West GM, Geoghegan KF. Emerging methods in chemoproteomics with relevance to drug discovery. Methods Mol Biol. 2017;1513:11–22.

Article  CAS  PubMed  Google Scholar 

Raina K, Crews CM. Chemical inducers of targeted protein degradation*. J Biol Chem. 2010;285:11057–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nowak RP, DeAngelo SL, Buckley D, He Z, Donovan KA, An J, et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat Chem Biol. 2018;14:706–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

An SN, Fu LW. Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs. eBioMedicine. 2018;36:553–62.

Article  PubMed  PubMed Central  Google Scholar 

Ge J, Li S, Weng G, Wang H, Fang M, Sun H, et al. PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters. Nucleic Acids Res. 2024;53:D1510–D5.

Article  Google Scholar 

Gao J, Yang L, Lei S, Zhou F, Nie H, Peng B, et al. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy. Sci Bull. 2023;68:1069–85.

Article  CAS  Google Scholar 

Farnaby W, Koegl M, Roy MJ, Whitworth C, Diers E, Trainor N, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019;15:672–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drummond ML, Williams CI. In silico modeling of PROTAC-mediated ternary complexes: validation and application. J Chem Inf Model. 2019;59:1634–44.

Article  CAS  PubMed  Google Scholar 

Gadd MS, Testa A, Lucas X, Chan K-H, Chen W, Lamont DJ, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017;13:514–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roy MJ, Winkler S, Hughes SJ, Whitworth C, Galant M, Farnaby W, et al. SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate. ACS Chem Biol. 2019;14:361–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hughes SJ, Ciulli A. Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders. Essays Biochem. 2017;61:505–16.

Article  PubMed  PubMed Central  Google Scholar 

Riching KM, Mahan S, Corona CR, McDougall M, Vasta JD, Robers MB, et al. Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action. ACS Chem Biol. 2018;13:2758–70.

Article  CAS  PubMed  Google Scholar 

Toure M, Crews CM. Small-molecule PROTACS: new approaches to protein degradation. Angew Chem Int Ed Engl. 2016;55:1966–73.

Article  CAS  PubMed  Google Scholar 

Choudhary D, Kaur A, Singh P, Chaudhary G, Kaur R, Bayan MF, et al. Target protein degradation by protacs: a budding cancer treatment strategy. Pharmacol Ther. 2023;250:108525.

Article  CAS  PubMed  Google Scholar 

Chen Y, Yang Q, Xu J, Tang L, Zhang Y, Du F, et al. PROTACs in gastrointestinal cancers. Mol Ther Oncolytics. 2022;27:204–23.

Article  PubMed  PubMed Central  Google Scholar 

Edmondson SD, Yang B, Fallan C. Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: recent progress and future challenges. Bioorg Med Chem Lett. 2019;29:1555–64.

Article  CAS  PubMed  Google Scholar 

Li Y, Wu Y, Gao S, Sun T, Jiang C. PROTAC delivery in tumor immunotherapy: where are we and where are we going? J Control Release. 2025;378:116–44.

Article  CAS  PubMed